Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug 17;2(8):100378.
doi: 10.1016/j.xcrm.2021.100378.

Psychotherapy-supported MDMA treatment for PTSD

Affiliations
Comment

Psychotherapy-supported MDMA treatment for PTSD

John H Krystal et al. Cell Rep Med. .

Abstract

A promising new Phase III study of MDMA plus psychotherapy for PTSD treatment by Mitchell and colleagues that appeared in Nature Medicine raises important new questions about the biology and optimal treatment of this disorder.

PubMed Disclaimer

Conflict of interest statement

Financial disclosures can be found in the supplemental information.

Comment on

  • MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
    Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot'alora G M, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, van der Kolk B, Tzarfaty K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, Hamilton S, Wang JB, Coker A, Matthews R, de Boer A, Yazar-Klosinski B, Emerson A, Doblin R. Mitchell JM, et al. Nat Med. 2021 Jun;27(6):1025-1033. doi: 10.1038/s41591-021-01336-3. Epub 2021 May 10. Nat Med. 2021. PMID: 33972795 Free PMC article. Clinical Trial.

Similar articles

Cited by

References

    1. Mitchell J.M., Bogenschutz M., Lilienstein A., Harrison C., Kleiman S., Parker-Guilbert K., Ot’alora G M., Garas W., Paleos C., Gorman I. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 2021;27:1025–1033. - PMC - PubMed
    1. Young M.B., Norrholm S.D., Khoury L.M., Jovanovic T., Rauch S.A.M., Reiff C.M., Dunlop B.W., Rothbaum B.O., Howell L.L. Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA) Psychopharmacology (Berl.) 2017;234:2883–2895. - PMC - PubMed
    1. Carhart-Harris R.L., Wall M.B., Erritzoe D., Kaelen M., Ferguson B., De Meer I., Tanner M., Bloomfield M., Williams T.M., Bolstridge M. The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int. J. Neuropsychopharmacol. 2014;17:527–540. - PubMed
    1. Kamboj S.K., Walldén Y.S.E., Falconer C.J., Alotaibi M.R., Blagbrough I.S., Husbands S.M., Freeman T.P. Additive Effects of 3,4-Methylenedioxymethamphetamine (MDMA) and Compassionate Imagery on Self-Compassion in Recreational Users of Ecstasy. Mindfulness (N Y) 2018;9:1134–1145. - PMC - PubMed
    1. Hake H.S., Davis J.K.P., Wood R.R., Tanner M.K., Loetz E.C., Sanchez A., Ostrovskyy M., Oleson E.B., Grigsby J., Doblin R., Greenwood B.N. 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. Physiol. Behav. 2019;199:343–350. - PMC - PubMed

Publication types

Substances